MIRA PHARMACEUTICALS, INC.
MIRANasdaq
$0.96
↑ +2.8%Jul 17 close · end-of-day
Price
1Y↓ -48.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-104.9%
ROIC
—
Debt / Equity
—
Net Cash
$9.4M
Return 1Y
-52.5%
Company profile
We are an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Our corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland.
- CEO
- Erez Aminov
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Florida
- Website
- www.mirapharmaceuticals.com
Earnings
MIRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.03↓ -72.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | -$7.1M | -$12.0M | -$7.9M | -$10.4M |
| Diluted EPS | -$0.40 | -$0.85 | -$0.51 | -$1.35 |
| Operating cash flow | -$5.6M | -$4.5M | -$5.6M | -$4.7M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q3 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$1.7M | -$2.0M | -$2.4M | -$1.8M | -$1.5M | -$1.1M | -$6.0M | -$1.2M |
| Diluted EPS | -$0.11 | -$0.14 | -$0.11 | -$0.11 | -$0.09 | -$1.18 | $0.03 | -$0.03 |
| Operating cash flow | -$863,929.00 | -$1.8M | -$1.8M | -$1.6M | -$799,651.00 | -$1.1M | -$1.1M | -$1.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-01 | Shekhat Denil Nanji | Award | 22,378 | $1.35 | $30,210.30 | filing |
| 2025-10-01 | Aminov Erez· Chief Executive Officer | Award | 2,685,456 | — | — | filing |
| 2025-08-29 | Aminov Erez· Chief Executive Officer | Award | 62,500 | $1.37 | $85,625.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.